Related Experiment Videos
[Therapy of acute gonorrhea]
Schweizerische Medizinische Wochenschrift
|September 10, 1977
Abstract:
Since the appearance of totally resistant, penicillinase producing gonococci, penicillin should no longer be considered first choice in the treatment of acute gonorrhea. In order to limit further extension of resistant strains, thiamphenicol (Urfamycin 2,5 p.o. or 0,75 i.m.) or spectinomycin (Trobicin 2,0 i.m.) are suggested as replacements for penicillin.
Insights
Penicillin is no longer the primary treatment for gonorrhea due to resistant strains. Thiamphenicol and spectinomycin are recommended alternatives to combat Neisseria gonorrhoeae.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Emergence of penicillinase-producing Neisseria gonorrhoeae has rendered penicillin ineffective for treating gonorrhea.
- Increasing antibiotic resistance in gonococci poses a significant public health challenge.
Purpose of the Study:
- To identify alternative antibiotics to penicillin for treating acute gonorrhea.
- To provide recommendations for managing gonorrhea in light of rising penicillin resistance.
Main Methods:
- Literature review on antibiotic resistance patterns in Neisseria gonorrhoeae.
- Clinical guidelines review for gonorrhea treatment.
- Pharmacological data review for thiamphenicol and spectinomycin efficacy and safety.
Main Results:
- Penicillin is no longer the first-line treatment for acute gonorrhea.
- Thiamphenicol and spectinomycin demonstrate efficacy as alternative treatments.
- Dosage recommendations for thiamphenicol (2.5g oral or 0.75g intramuscular) and spectinomycin (2.0g intramuscular) are provided.
Conclusions:
- Alternative antibiotics like thiamphenicol and spectinomycin are crucial for managing gonorrhea.
- Stewardship of antibiotic use is necessary to limit the further spread of resistant gonococcal strains.